> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Regulatory Review Period Determined for Siliq
- URL: https://www.fdaweb.com/regulatory-review-period-determined-for-siliq/
- Published: 2018-10-23T12:00:00.000Z
- Updated: 2026-09-15T00:39:55.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5142651

*Federal Register* notice: FDA has determined for patent extension-related purposes the regulatory review period for Kirin-Amgen’s Siliq (brodalumab), indicated for treating moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy and have failed to respond or have lost response to other systemic therapies. The regulatory review period was determined to be 3,101days, which included 2,643 days that occurred during the testing phase and 458 days during the approval phase. To view the notice, click [here](https://s3.amazonaws.com/public-inspection.federalregister.gov/2018-23058.pdf?ref=fdaweb.com).